title: The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents.
abstract: In cancer biology, mesenchymal stem cells (MSCs) display aspects that can appear contradictory. On one hand, these cells possess several features which give them the ability to specifically target and then sustain cancer cells in their ability to survive the multifaceted host response against cancer. On the other hand, due to this excellent aptitude to home-in on tumor tissues, regardless their location in the host's body, MSCs are considered to be extremely selective vehicles to reach cancer cells specifically. Recently, MSC sustainment of cancer cell growth is a hot research topic. Indeed, these cells are known to sustain tumor angiogenesis and metastasis formation, to create a microenvironment favorable for cancer cell growth and to down-modulate the immune system capabilities in the host organism. On the other hand, since scientists became able to take advantage of their extremely selective capability to target cancer cells, MSCs are now also thought of in a different light. Indeed, MSCs are now considered a promising vehicle for local expression or delivery of even particularly toxic anticancer agents, ranging from Herpes Simplex Virus to locally-acting antineoplastic drugs. On this basis, investigation is now focused on how to impair the pro-neoplastic features of MSCs on one hand whilst taking advantage of their specific tropism toward cancer cells, on the other. As with the two faces of Janus, this review will concisely explore the research activity in these two apparently conflicting fields.
authors: Umberto Galderisi, Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, PA 19122, United States.
authors: Umberto
authors: U
authors: Galderisi
authors: Antonio
authors: A
authors: Giordano
authors: Marco G
authors: MG
authors: Paggi
references: J Thromb Haemost. 2007 Apr;5(4):826-34
references: 17229052
references: Cancer Res. 2004 Dec 1;64(23):8492-5
references: 15574751
references: Ageing Res Rev. 2006 Feb;5(1):91-116
references: 16310414
references: Leukemia. 2007 Feb;21(2):304-10
references: 17170725
references: Nature. 2007 Oct 4;449(7162):557-63
references: 17914389
references: Stem Cells. 1995 Sep;13(5):477-86
references: 8528097
references: Cancer Res. 2007 Jul 1;67(13):6304-13
references: 17616689
references: Gene Ther. 2003 Apr;10(8):621-9
references: 12692590
references: Blood. 2001 Nov 1;98(9):2615-25
references: 11675329
references: Blood. 2003 Nov 15;102(10):3837-44
references: 12881305
references: Cancer Res. 2009 Jun 1;69(11):4791-9
references: 19487291
references: Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2397-402
references: 12606728
references: Circ Res. 2004 Mar 19;94(5):678-85
references: 14739163
references: Mol Cancer Ther. 2006 Mar;5(3):755-66
references: 16546991
references: J Cell Biochem. 2004 Apr 15;91(6):1146-58
references: 15048870
references: Nature. 2003 Oct 23;425(6960):841-6
references: 14574413
references: Cancer Res. 2007 Nov 15;67(22):10889-98
references: 18006834
references: Breast Cancer Res Treat. 2007 Oct;105(2):157-67
references: 17221158
references: Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7
references: 19264968
references: Oncogene. 2004 Jun 24;23(29):5092-4
references: 15107816
references: J Cell Sci. 2004 Jun 15;117(Pt 14):2971-81
references: 15173316
references: Stem Cells. 2004;22(3):377-84
references: 15153614
references: Cell Death Differ. 2005 Jan;12(1):65-77
references: 15459751
references: Science. 1997 Apr 4;276(5309):71-4
references: 9082988
references: Cancer Res. 2005 Apr 15;65(8):3035-9
references: 15833829
references: Nat Med. 2003 Sep;9(9):1158-65
references: 12897778
references: Tissue Eng. 2005 May-Jun;11(5-6):896-903
references: 15998229
references: J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603
references: 15523088
references: Exp Hematol. 2000 Aug;28(8):875-84
references: 10989188
references: Handb Exp Pharmacol. 2007;(180):263-83
references: 17554513
references: Int J Cardiol. 2005 Dec 7;105(3):274-82
references: 16274768
references: Nature. 2003 Oct 23;425(6960):836-41
references: 14574412
references: Circulation. 2005 Jan 18;111(2):150-6
references: 15642764
references: Stem Cells. 2001;19(3):180-92
references: 11359943
references: Cancer Res. 2005 Apr 15;65(8):3307-18
references: 15833864
references: J Cell Mol Med. 2011 Feb;15(2):433-44
references: 19799647
references: Exp Hematol. 2005 Sep;33(9):965-70
references: 16140143
references: Cancer Res. 2002 Jul 1;62(13):3603-8
references: 12097260
references: Exp Dermatol. 2006 Nov;15(11):865-74
references: 17002683
references: Clin Cancer Res. 2007 Sep 1;13(17):5020-7
references: 17785552
references: J Immunol. 2007 Aug 1;179(3):1595-604
references: 17641026
references: Science. 1999 Apr 2;284(5411):143-7
references: 10102814
references: Oncogene. 2004 Jun 24;23(29):5095-8
references: 15107831
references: J Clin Invest. 2000 Jun;105(12):1663-8
references: 10862779
references: Blood. 2006 Nov 15;108(10):3245-52
references: 16857992
references: Handb Exp Pharmacol. 2006;(174):249-82
references: 16370331
references: Stem Cells. 2007 Jul;25(7):1761-8
references: 17395769
references: Stem Cells. 2006 Apr;24(4):1030-41
references: 16253981
references: Int J Cancer. 2005 Jul 20;115(6):885-92
references: 15729726
references: J Gene Med. 2009 May;11(5):373-81
references: 19274675